1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Biogen/Elan hope updated Tysabri label will lend confidence to patients/prescribers

 
• By Sukaina Virji

The EC has approved the inclusion of anti-JC virus (JCV) antibody status to Biogen Idec/Elan's Tysabri (natalizumab) label "to aid in stratifying patients at risk for developing progressive multifocal leukoencephalopathy (PML)". Long-term growth potential of Tysabri could be dependent on patient risk stratification for PML, but it not yet clear what proportion of potential Tysabri patents would be tested for JCV status.

The EC has approved the inclusion of anti-JC virus (JCV) antibody status to Biogen Idec/Elan's Tysabri (natalizumab) label "to aid in stratifying patients at risk for developing progressive multifocal leukoencephalopathy (PML)". Long-term growth potential of Tysabri could be dependent on patient risk stratification for PML, but it not yet clear what proportion of potential Tysabri patents would be tested for JCV status.

Biogen Idec has said previously that it sees the "anti-JCV antibody assay as one of its most advanced initiatives" to potentially help do this, as sales of Tysabri have been...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

More from Therapeutic Category

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.